2026-10-15T07:26:02Z https://data.mendeley.com/oai

oai:data.mendeley.com/4dcgs8mvzx.3 2022-12-16T08:02:39Z

REN, Ping RAMIHM generates fully human monoclonal antibodies by rapid mRNA immunization of humanized mice and BCR-seq Mendeley Data As a clinical vaccine, lipid nanoparticle (LNP) mRNA demonstrated potent and broad antibody responses, leading to speculation about its potential for antibody discovery. Here, we developed RAMIHM, a highly efficient strategy for developing fully human monoclonal antibodies that employs rapid mRNA immunization of humanized mice followed by single B cell sequencing (scBCR-seq). We immunized humanized transgenic mice with RAMIHM and generated 15 top-ranked clones from peripheral blood, plasma B, and memory B cell populations, demonstrating a high rate of antigen-specificity (93.3%). Two Omicron-specific neutralizing antibodies with high potent and one broad-spectrum neutralizing antibody were discovered. Furthermore, we extended the application of RAMIHM to cancer immunotherapy targets, including a single transmembrane protein CD22 and a multi-transmembrane GPCR target, GPRC5D, which is difficult for traditional protein immunization methods. RAMIHM-scBCR-seq is a broadly applicable platform for the rapid and efficient development of fully human monoclonal antibodies against an assortment of targets. Flow Cytometry Lei, Peng Yang, Luojia Suzuki, Kazushi Fang, Zhenhao Renauer, Paul Lin, Qianqian Bai, Meizhu Li, Tongqing Clark, Paul Klein, Deryl Chen, Sidi Dataset doi:10.17632/4dcgs8mvzx.3 oai:data.mendeley.com/4dcgs8mvzx.3 Creative Commons Attribution 4.0 International http://creativecommons.org/licenses/by/4.0 https://data.mendeley.com/datasets/4dcgs8mvzx 2022-12-16T08:02:39Z